Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
betulinic acid
docetaxel
drug interaction
melanoma
paclitaxel
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
28
07
2022
revised:
23
08
2022
accepted:
24
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
The incidence of melanoma is steadily increasing worldwide. Melanoma is the most lethal skin cancer, and new therapeutic methods are being sought. Our research aimed to investigate the cytotoxic and antiproliferative effects of betulinic acid in vitro, used alone and in combination with taxanes (paclitaxel, docetaxel) in four melanoma cell lines. Isobolographic analysis allowed us to assess the interactions between these compounds. Betulinic acid had no cytotoxic effect on normal human keratinocyte HaCaT cells; the amount of LDH released by them was significantly lower compared to melanoma cell lines. The present study shows that betulinic acid significantly inhibits the growth of melanoma cell lines in vitro. The IC50 values of betulinic acid ranged from 2.21 µM to 15.94 µM against the four melanoma lines. Co-treatment of betulinic acid with paclitaxel or docetaxel generated desirable drug-drug interactions, such as an additive and additive with a tendency to synergy interactions.
Identifiants
pubmed: 36077036
pii: ijms23179641
doi: 10.3390/ijms23179641
pmc: PMC9456196
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Pentacyclic Triterpenes
0
Taxoids
0
Docetaxel
15H5577CQD
Paclitaxel
P88XT4IS4D
Betulinic Acid
4G6A18707N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CSP VA
ID : 474
Pays : United States
Références
J Clin Oncol. 2013 Jan 20;31(3):373-9
pubmed: 23248256
J Pharmacol Exp Ther. 2004 Sep;310(3):981-6
pubmed: 15175417
Oncol Rep. 2017 Oct;38(4):2360-2368
pubmed: 28791404
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Cell Death Dis. 2018 May 25;9(6):636
pubmed: 29802332
Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):105-14
pubmed: 17333129
Int J Mol Sci. 2021 Mar 27;22(7):
pubmed: 33801689
Oncol Rep. 2015 Aug;34(2):1058-64
pubmed: 26059173
Molecules. 2021 Feb 19;26(4):
pubmed: 33669817
Int J Clin Exp Pathol. 2015 Jan 01;8(1):252-9
pubmed: 25755712
J Cell Mol Med. 2001 Oct-Dec;5(4):402-8
pubmed: 12067474
Eur J Cancer. 1997 Mar;33(3):463-70
pubmed: 9155533
J Pharmacol Exp Ther. 2006 Oct;319(1):1-7
pubmed: 16670349
Cancers (Basel). 2021 Sep 30;13(19):
pubmed: 34638427
J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
pubmed: 18152921
Mol Cancer. 2010 Jul 09;9:182
pubmed: 20618955
Mayo Clin Proc. 2007 Mar;82(3):364-80
pubmed: 17352373
Cancers (Basel). 2021 Jun 18;13(12):
pubmed: 34207200
Neurochem Res. 2017 Apr;42(4):1130-1140
pubmed: 28124213
Int J Mol Sci. 2022 Jun 17;23(12):
pubmed: 35743195
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
Molecules. 2021 Oct 15;26(20):
pubmed: 34684834
Aging (Albany NY). 2016 Apr;8(4):603-19
pubmed: 27019364
Int J Mol Sci. 2021 Jun 15;22(12):
pubmed: 34203771
Colloids Surf B Biointerfaces. 2019 Feb 1;174:270-279
pubmed: 30469048
Front Genet. 2021 Apr 09;12:663110
pubmed: 33897771
Crit Rev Oncol Hematol. 2020 Jan;145:102831
pubmed: 31783290
Curr Protoc Pharmacol. 2016 Mar 18;72:9.19.1-9.19.19
pubmed: 26995550
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):122-131
pubmed: 30967685
Int J Mol Sci. 2022 Jul 11;23(14):
pubmed: 35886997
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393886
Int J Mol Sci. 2014 May 09;15(5):8235-55
pubmed: 24821543
Antioxidants (Basel). 2022 Mar 23;11(4):
pubmed: 35453297
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337925
Cancer. 2019 Feb 1;125(3):463-472
pubmed: 30383888
J Asian Nat Prod Res. 2014 Jan;16(1):34-42
pubmed: 24350921
Cell Mol Biol Lett. 2019 Jun 13;24:40
pubmed: 31223315
Biotechnol Adv. 2020 Jan - Feb;38:107409
pubmed: 31220568
Clin Cancer Res. 2017 Jul 15;23(14):3489-3498
pubmed: 28364015
Cytometry A. 2020 Dec;97(12):1265-1275
pubmed: 32790129
Cancer Lett. 2002 Jan 10;175(1):17-25
pubmed: 11734332
Oncol Lett. 2018 Sep;16(3):3628-3634
pubmed: 30127971
Biomed Pharmacother. 2017 Apr;88:349-358
pubmed: 28119237
Int J Pharm. 2017 Oct 5;531(1):153-166
pubmed: 28823888
Chem Biol Interact. 2021 Jan 5;333:109326
pubmed: 33245928
Anticancer Drugs. 1996 Jun;7(4):493-8
pubmed: 8826619
Int J Mol Sci. 2021 Jan 07;22(2):
pubmed: 33430369
Ital J Dermatol Venerol. 2021 Jun;156(3):322-330
pubmed: 33982545
Cancer Chemother Pharmacol. 2018 Aug;82(2):353-360
pubmed: 29943192
Pharmacol Ther. 2007 Jan;113(1):197-209
pubmed: 17079019
Int J Cancer. 1998 Jan 19;75(2):317-23
pubmed: 9462725
Cells. 2021 Sep 05;10(9):
pubmed: 34571969
J Pharmacol Toxicol Methods. 2015 May-Jun;73:1-6
pubmed: 25681780
Anticancer Agents Med Chem. 2014;14(7):936-45
pubmed: 24568161
Environ Toxicol. 2018 Nov;33(11):1153-1159
pubmed: 30136359
Int J Mol Sci. 2018 Oct 19;19(10):
pubmed: 30347681
Oxid Med Cell Longev. 2019 Jun 9;2019:5083158
pubmed: 31281581